Kelin

Kelun-Biotech is a China-based biopharmaceutical company focused on discovery, development, manufacturing, and commercialization of innovative medicines, with particular strength in oncology and selected immunology programs. The company has built core technology platforms spanning antibody-drug conjugates, biologics, and small molecules, and has advanced one of the more visible ADC pipelines in China. Its lead asset, sacituzumab tirumotecan, has achieved multiple approvals in China, while additional late-stage assets include trastuzumab botidotin, tagitanlimab, cetuximab N01, and a selective RET inhibitor. Kelun-Biotech also maintains in-house clinical, manufacturing, quality, and translational medicine capabilities and has partnered with MSD on multiple ADC assets outside Greater China. The requested name "Kelin" does not appear to be the exact company name; the closest relevant healthcare company match is Kelun-Biotech.